腫瘍生物学


Achievement



Home
Message
Research
Member
Achievement
Picture
Contact
Link
2

原著論文


2023年

  1. Suzuki MM, Iijima K, Ogami K, Shinjo K, Murofushi Y, Xie J, Wang X, Kitano Y, Mamiya A, Kibe Y, Nishimura T, Ohka F, Saito R, Sato S, Kobayashi J, Yao R, Miyata K, Kataoka K, Suzuki HI, Kondo Y. TUG1-mediated R-loop resolution at microsatellite loci as a prerequisite for cancer cell proliferation. Nat Commun. 2023 Aug 22;14(1):4521.PMID: 37607907
  2. Muraoka A, Suzuki M, Hamaguchi T, Watanabe S, Iijima K , Murofushi Y ,Shinjo K, Osuka S, Hariyama Y, Ito M, Ohno K, Kiyono T, Kyo S, Iwase A, Kikkawa F, Kajiyama H, Kondo Y. Fusobacterium infection facilitates the development of endometriosis through the phenotypic transition of endometrial fibroblasts. Sci Transl Med. 2023 Jun 14;15(700):eadd1531.PMID: 37315109
  3. Yamaguchi J, Ohka F, Kitano Y, Maeda S, Motomura K, Aoki K, Takeuchi K, Nagata Y, Hattori H, Tsujiuchi T, Motomura A, Nishikawa T, Kibe Y, Shinjo K, Kondo Y, Saito R. Rapid detection of the MYD88 L265P mutation for pre- and intra-operative diagnosis of primary central nervous system lymphoma. Cancer Sci.2023 Jun;114(6):2544-2551.PMID: 36859777
  4. Imai K, Ishimoto T, Doke T, Tsuboi T, Watanabe Y, Katsushima K, Suzuki M, Oishi H, Furuhashi K, Ito Y, Kondo Y, Maruyama S. Long non-coding RNA lnc-CHAF1B-3 promotes renal interstitial fibrosis by regulating EMT-related genes in renal proximal tubular cells.Mol Ther Nucleic Acids. 2022 Dec 23;31:139-150.PMID: 36700051
  5. Yamaguchi J, Ohka F, Lushun C, Motomura K, Aoki K, Takeuchi K, Nagata Y, Ito S, Mizutani N, Ohno M, Suzaki N, Takasu S, Seki Y, Kano T, Wakabayashi K, Oyama H, Kurahashi S, Tanahashi K, Hirano M, Shimizu H, Kitano Y, Maeda S, Yamazaki S, Wakabayashi T, Kondo Y, Natsume A, Saito R. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.Cancer Med. 2023 Mar;12(6):7116-7126. PMID: 36478416

    6. 2022年

    1. Matsumoto Y, Shinjo K, Mase S, Fukuyo M, Aoki K, Ozawa F, Yoshihara H, Goto S, Kitaori T, Ozaki Y, Takahashi S, Kaneda A, Sugiura-Ogasawara M, Kondo Y. Characteristic DNA methylation profiles of chorionicvilli in recurrent miscarriage.Sci Rep 2022 Jul 27;12(1):11673. PMID: 35896560
    2. Suehiro Y, Suenaga S, Kunimune Y, Yada S, Hamamoto K, Tsuyama T, Amano S, Matsui H, Higaki S, Fujii I, Suzuki C, Hoshida T, Matsumoto T, Fujimoto Y, Kaino S, Shinjo K, Kondo Y, Sakaida I, Takami T, Nagano H, Yamasaki T. CA19-9 in Combination with Methylated HOXA1 and SST Is Useful to Diagnose Stage I Pancreatic Cancer.Oncology. 2022; 100(12):674-684.PMID: 36244341

      3. 2021年

      1. Yamazaki S, Ohka F, Hirano M, Shiraki Y, Motomura K, Tanahashi K, Tsujiuchi T, Motomura A, Aoki K, Shinjo K, Murofushi Y, Kitano Y, Maeda S, Kato A, Shimizu H, Yamaguchi J, Adilijiang A, Wakabayashi T, Saito R, Enomoto A, Kondo Y, Natsume A. Newly Established Patient-derived Organoid Model of Intracranial Meningioma.Neuro Oncol. 2021 Nov 23(11): 1936-1948. PMID: 34214169

        2. 2020年

        1. Tasaki T, Suzuki M, Katsushima K, Shinjo K, Iijima K, Murofushi Y, Naiki-Ito A, Hayashi K, Qiu C, Takahashi A, Tanaka Y, Kawaguchi T, Sugawara M, Kataoka T, Taito M, Miyata K, Kataoka K, Noda T, Gao W, Kataoka H, Takahashi S, Kimura K, Kondo Y. Cancer-specific targeting of taurine upregulated gene 1 enhances the effects of chemotherapy in pancreatic cancer. Cancer Res. 2021 ; canres.3021.2020. PMID: 33648930
        2. Kato H, Kushima I, Mori D, Yoshimi A, Branko A, Nawa Y, Toyama M, Furuta S, Yanjie Yu, Ishizuka K, Kimura H, Arioka Y, Tsujimura K, Morikawa M, Okada T, Inada T, Nakatochi M, Shinjo K, Kondo Y, Kaibuchi K, Funabiki Y, Kimura R, Suzuki T, Yamakawa K, Ikeda M, Iwata N, Takahashi T, Suzuki M, Okahisa Y, Takaki M, Egawa J, Someya T, Ozaki N. Rare genetic variants in the gene encoding histone lysine demethylase 4C (KDM4C) and their contributions to susceptibility to schizophrenia and autism spectrum disorder. Transl Psychiatry. 2020 ; 10(1): 421. PMID: 33279929
        3. Muraoka A, Osuka S, Kiyono T, Suzuki M, Yokoi A, Murase T, Nishino K, Niimi K, Nakamura T, Goto M, Kajiyama H, Kondo Y, Kikkawa F. Establishment and characterization of cell lines from human endometrial epithelial and mesenchymal cells from patients with endometriosis. Fertil Steril Sci. 2020 ; 2 (2): 195-205. PMID: 32891059
        4. Suenaga M, Fujii T, Yamada S, Hayashi M, Shinjo K, Takami H, Niwa Y, Sonohara F, Shimizu D, Kanda M, Kobayashi D, Tanaka C, Nakayama G, Koike M, Fujiwara M, Kondo Y, Kodera Y. Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2020 PMID: 32875467
        5. Hirata E, Ishibashi K, Kohsaka S, Shinjo K, Kojima S, Kondo Y, Mano H, Yano S, Kiyokawa E, Sahai E. The Brain Microenvironment Induces DNMT1 Suppression and Indolence of Metastatic Cancer Cells.　iScience. 2020 23(9):101480. PMID: 32891059
        6. Totani H, Shinjo K, Suzuki M, Katsushima K, Mase S, Masaki A, Ito A, Masaki R, Kusumoto S, Komatsu H, Ishida T, Inagaki H, Iida S, Kondo Y. Autocrine HGF/c-Met signaling pathway confers aggressiveness in lymph node adult T-cell leukemia/lymphoma. Oncogene. 2020 39(35):5782-5794. PMID: 32747750
        7. Shinjo K, Hara K, Nagae G, Umeda T, Katsushima K, Suzuki M, Murofushi Y, Umezu Y, Takeuchi I, Takahashi S, Okuno Y, Matsuo K, Ito H, Tajima S, Aburatani H, Yamao K, Kondo Y. A Novel Sensitive Detection Method for DNA Methylation in Circulating Free DNA of Pancreatic Cancer. PLoS One. 2020 ;15(6):e0233782. PMID: 32520974
        8. Maeda S, Ohka F, Okuno Y, Aoki K, Motomura K, Takeuchi K, Kusakari H, Yanagisawa N, Sato S, Yamaguchi J, Tanahashi K, Hirano M, Kato A, Shimizu H, Kitano Y, Yamazaki S, Yamashita S, Takeshima H, Shinjo K, Kondo Y, Wakabayashi T, Natsume A. H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant. Acta Neuropathol Commun. 2020 ; 8(1) : 8. PMID: 32019606

        ▲ページ先頭へ

        2019年

        1. Ohka F, Shinjo K, Deguchi S, Matsui Y, Okuno Y, Katsushima K, Suzuki M, Kato A, Ogino N, Yamamichi A, Aoki K, Suzuki H, Sato S, Arul Rayan N, Prabhakar S, Göke J, Shimamura T, Maruyama R, Takahashi S, SUzumura A, Kimura H, Wakabayashi T, Zong H, Natsume A, Kondo Y. Pathogeneic Epigenetic Consequences of Genetic Alterations in IDH-Wild-Type Diffuse Astrocytic Gliomas. Cancer Res. 2019; 79(19):4814-27. PMID: 31431463
        2. Murashima A, Shinjo K, Katsushima K, Onuki T, Kondoh Y, Osada H, Kagaya N, Shinya K, Kimura H, Yoshida M, Murakami S, Kondo Y. Identification of a Chemical Modulator of EZH2-mediated Silencing by Cell-based High-throughput Screening Assay. J Biochem. 2019 PMID: 30690451　（第28回JB論文賞を受賞しました！）
        3. Kondo N, Tohnai G, Sahashi K, Iida M, Kataoka M, Nakatsuji H, Tsutsumi Y, Hashizume A, Adachi H, Koike H, Shinjo K, Kondo Y, Sobue G, Katsuno M. DNA methylation inhibitor attenuates polyglutamine-induced neurodegeneration by regulating Hes5. EMBO Mol Med. 2019 PMID: 30940675
        4. Watanabe S, Hayashi K, Toh K, Kim HJ, Liu X, Chaya H, Fukushima S, Katsushima K, Kondo Y, Uchida S, Ogura S, Nomoto T, Takemoto H, Cabral H, Kinoh H, Tanaka HY, Kano MR, Matsumoto Y, Fukuhara H, Uchida S, Nangaku M, Osada K, Nishiyama N, Miyata K, Kataoka K. In vivo rendezvous of small nucleic acid drugs with charge-matched block catiomers to target cancers. Nat Commun. 2019 Apr 24;10(1):1894. PMID: 31019193
        5. Mase S, Shinjo K, Totani H, Katsushima K, Arakawa A, Takahashi S, Lai HC, Lin RI, Chan MWY, Sugiura-Ogasawara M, Kondo Y. ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer. Cancer Sci. 2019; 110:1105-1116, PMID: 30633424

        ▲ページ先頭へ

        2018年

        1. Hirano M, Ohka F, Maeda S, Chalise L, Yamamichi A, Aoki K, Kato A, Tanahashi K, Motomura K, Nishimura Y, Hara M, Shinjo K, Kondo Y, Wakabayashi T, Natsume A. A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR. Brain Tumor Pathol. 2018; 35: 97-105, PMID: 29460200 .

        ▲ページ先頭へ

        2017年

        1. Minami N, Maeda Y, Shibao S, Arima Y, Ohka F, Kondo Y, Maruyama K, Kusuhara M, Sasayama T, Kohmura E, Saya H, Sampetrean O. Organotypic brain explant culture as a drug evaluation system for malignant brain tumors. Cancer Med. 2017; 6: 2635-2645, PMID: 28980419 .
        2. Deguchi S, Katsushima K, Hatanaka A, Shinjo K, Ohka F, Wakabayashi T, Zong H, Natsume A, Kondo Y.Oncogenic effects of evolutionarily conserved noncoding RNA ECONEXIN on gliomagenesis. Oncogene. 20176 Apr 3.doi: 10.1038/onc.2017.88. [Epub ahead of print]. PMID: [Epub ahead of print]28368417 .

        ▲ページ先頭へ

        2016年

        1. Katsushima K, Natsume A, Ohka F, Shinjo K, Hatanaka A, Ichimura N, Sato S, Takahashi S, Kimura H, Totoki Y, Shibata T, Naito M, Kim HJ, Miyata K, Kataoka K, Kondo Y. Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment. Nat Commun. 2016 Dec 6;7:13616. PMID: [Epub ahead of print]27922002 .
        2. Fujii S, Shinjo K, Matsumoto S, Harada T, Nojima S, Sato S, Usami Y, Toyosawa S, Morii E, Kondo Y, Kikuchi A.Epigenetic upregulation of ARL4C, due to DNA hypomethylation in the 3'-untranslated region, promotes tumorigenesis of lung squamous cell carcinoma. Oncotarget. 2016 Dec 6;7(49):81571-81587. PMID: [Epub ahead of print]27835592 .
        3. Murakami-Tonami Y, Ikeda H, Yamagishi R, Inayoshi M, Inagaki S, Kishida S, Komata Y, Jan Koster, Takeuchi I, Kondo Y, Maeda T, Sekido Y, Murakami H, Kadomatsu K. SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells. Sci Rep. 2016 Aug 19;6:31615. PMID: [Epub ahead of print] 27539729.
        4. Torigata K, Okuzaki D, Mukai S, Hatanaka A, Ohka F, motooka D, Nakamura S, Ohkawa Y, Yabuta N, Kondo Y, Nojima H. LATS2 positively regulates Polycomb repressive complex 2. PLOS One. 2016 Jul 19;11: e0158562. PMID: [Epub ahead of print]27434182.
        5. Sato S, Katsushima K, Shinjo K, Hatanaka A, Ohka F, Suzuki S, Naiki-Ito A, Soga N, Takahashi S, Kondo Y. Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320-Mediated Suppression of the Androgen Receptor. Cancer Res. 2016 May 23: e0115350. PMID: [Epub ahead of print] 27216188.
        6. Nohara K, Okamura K, Suzuki T, Murai H, Ito T, Shinjo K, Takumi S, Michikawa T, Kondo Y, Hata K. Augmenting effects of gestational arsenite exposure of C3H mice on the hepatic tumors of the F2 male offspring via the F1 male offspring. J Appl Toxicol. 2016 ; jat.3149 : e0115350. PMID: 25825268.

        ▲ページ先頭へ

        2015年

        1. Fujii S, Srivastava V, Hegde A, Kondo Y, Shen L, Hoshino K, Gonzalez Y, Wang J, Sasai K, Ma X, Katayama H, Estecio MR, Hamilton SR, Wistuba I, Issa JP, Sen S. Regulation of AURKC expression by CpG island methylation in human cancer cells. Tumour Biol. PMID: [Epub ahead of print]. 25990457.
        2. Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, Shimamura T, Niida A, Motomura K, Ohka F, Yamamoto T, Tanahashi K, Ranjit M, Wakabayashi T, Yoshizato T, Kataoka K, Yoshida K, Nagata Y, Sato- Otsubo A, Tanaka H, Sanada M, Kondo Y, Nakamura H, Mizoguchi M, Abe T, Muragaki Y, Watanabe R, Ito I, Miyano S, Natsume A, Ogawa S. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. 2015 ; 47 : 458-68 . PMID: 25848751.
        3. Ichimura N, Shinjo K, An B, Shimizu Y, Yamao K, Ohka F, Katsushima K, Hatanaka A, Tojo M, Yamamoto E, Suzuki H, Ueda M, Kondo Y. Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer. Cancer Prev Res (Phila). 2015 Jun 10; PMID: 26063725.
        4. Gao W, Gu Y, Li Z, Cai H, Peng Q, Tu M, Kondo Y, Shinjo K, Zhu Y, Zhang J, Sekido Y, Han B, Qian Z, Miao Y. miR-615-5p is epigenetically inactivated and functions as a tumor suppressor in pancreatic ductal adenocarcinoma. Oncogene. 2015 ; 34 : 1629-40 . PMID: 24769899.
        5. Ishikawa K, Tsunekawa S, Ikeniwa M, Izumoto T, Iida A, Ogata H, Uenishi E, Seino Y, Ozaki N, Sugimura Y, Hamada Y, Kuroda A, Shinjo K, Kondo Y, Oiso Y. Long-Term Pancreatic Beta Cell Exposure to High Levels of Glucose but Not Palmitate Induces DNA Methylation within the Insulin Gene Promoter and Represses Transcriptional Activity. adenocarcinoma. Oncogene. PLoS One. 2015 ; 10 : e0115350. PMID: 25658116.
        6. Tanaka I, Osada H, Fujii M, Fukatsu A, Hida T, Horio Y, Kondo Y, Sato A, Hasegawa Y, Tsujimura T, Sekido Y. LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade. Oncogene. 2015 : 34 : 73-83 PMID: 24336325.

        ▲ページ先頭へ

        2014年

        1. Murakami-Tonami Y, Kishida S, Takeuchi I, Katou Y, Maris JM, Ichikawa H, Kondo Y, Sekido Y, Shirahige K, Murakami H, Kadomatsu K. Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells. Cell Cycle. 2014 ; 13 : 1115-31 . PMID: 24553121.
        2. Tahara T, Yamamoto E, Madireddi P, Suzuki H, Maruyama R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T, Kondo Y, Toyota M, Issa JP, Estécio MR. Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators. Gastroenterology. 2014; 146: 530-38. PMID: 24211491.
        3. Tahara T, Yamamoto E, Suzuki H, Maruyama R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T, An B, Shureiqi I, Toyota M, Kondo Y, Estécio MR, Issa JP. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 2014; 74: 1311-8. PMID: 24385213.
        4. Okamoto Y, Shinjo K, Shimizu Y, Sano T, Yamao K, Gao W, Fujii M, Osada H, Sekido Y, Murakami S, Tanaka Y, Joh T, Sato S, Takahashi S, Wakita T, Zhu J, Issa JP, Kondo Y. Hepatitis virus infection affects DNA methylation in mice with humanized livers. Gastroenterology. 2014; 146: 562-72. PMID: 24184133.
        5. Fukatsu A, Ishiguro F, Tanaka I, Kudo T, Nakagawa K, Shinjo K, Kondo Y, Fujii M, Hasegawa Y, Tomizawa K, Mitsudomi T, Osada H, Hata Y, Sekido Y. RASSF3 downregulation increases malignant phenotypes of non-small cell lung cancer. Lung Cancer. 2014 ; 83 : 23-9 . PMID: 24246507.

        ▲ページ先頭へ

        2013年

        1. Natsume A, Ito M, Katsushima K, Ohka F, Hatanaka A, Shinjo K, Sato S, Takahashi S, Ishikawa Y, Takeuchi I, Shimogawa H, Uesugi M, Okano H, Kim SU, Wakabayashi T, Issa JP, Sekido Y, Kondo Y. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma. Cancer Res. 73: 4559-70, 2013. PMID: 23720055.
        2. Xue X, Gao W, Sun B, Xu Y, Han B, Wang F, Zhang Y, Sun J, Wei J, Lu Z, Zhu Y, Sato Y, Sekido Y, Miao Y, Kondo Y. Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma. Oncogene. 2013; 32: 1724-34. PMID: 22614011.
        3. Ishiguro F, Murakami H, Mizuno T, Fujii M, Kondo Y, Usami N, Taniguchi T, Yokoi K, Osada H, Sekido Y. Membranous expression of activated leukocyte cell adhesion molecule contributes to poor prognosis and malignant phenotypes of non-small-cell lung cancer. J Surg Res. 2013; 179: 24-32. PMID: 22985775.

        ▲ページ先頭へ

        2012年

        1. Oki Y, Kondo Y, Yamamoto K, Ogura M, Kasai M, Kobayashi Y, Watanabe T, Uike N, Ohyashiki K, Okamoto SI, Ohnishi K, Tomita A, Miyazaki Y, Tohyama K, Mukai HY, Hotta T, Tomonaga M. A phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan. Cancer Sci. 2012; 103: 1839-47. PMID: 22816487.
        2. Katsushima K, Shinjo K, Natsume A, Ohka F, Fujii M, Osada H, Sekido Y, Kondo Y. Contribution of microRNA-1275 to Claudin11 suppression via a polycomb-mediated silencing mechanism in human glioma stem-like cells. J Biol Chem. 2012; 287: 27396-406. PMID: 22736761.
        3. Shinjo K, Okamoto Y, An B, Yokoyama T, Takeuchi I, Fujii M, Osada H, Usami N, Hasegawa Y, Ito H, Hida T, Fujimoto N, Kishimoto T, Sekido Y, Kondo Y. Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. Carcinogenesis. 2012; 33: 1277-85. PMID: 22532250.
        4. Murata T, Kondo Y, Sugimoto A, Kawashima D, Saito S, Isomura H, Kanda T, Tsurumi T. Epigenetic Histone Modification of Epstein-Barr virus BZLF1 Promoter during Latency and Reactivation in Raji Cells. Journal of Virology. 2012; 86: 4752-61. PMID: 22357272.
        5. Ishiguro F, Murakami H, Mizuno T, Fujii M, Kondo Y, Usami N, Yokoi K, Osada H, Sekido Y. Activated Leukocyte Cell Adhesion Molecule (ALCAM) Promotes Malignant Phenotypes of Malignant Mesothelioma. Journal of Thoracic Oncology. 2012; 7: 890-9. PMID: 22722789.
        6. Kishida Y, Natsume A, Toda H, Toi Y, Motomura K, Koyama H, Matsuda K, Nakayama O, Sato M, Suzuki M, Kondo Y, Wakabayashi T. Correlation between quantified promoter methylation and enzymatic activity of O6-methylguanine-DNA methyltransferases in glioblastomas. Tumour Biol. 2012; 33: 373-81. PMID: 22274924.
        7. Mizuno T, Murakami H, Fujii M, Ishiguro F, Tanaka I, Kondo Y, Akatsuka S, Toyokuni S, Yokoi K, Osada H, Sekido Y. YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. Oncogene. 2012; 31: 5117-22. PMID: 22286761.
        8. Fujii M, Toyoda T, Nakanishi H, Yatabe Y, Sato A, Matsudaira Y, Ito H, Murakami H, Kondo Y, Kondo E, Hida T, Tsujimura T, Osada H, Sekido Y. TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med. 2012; 209: 479-94. PMID: 22329991.
        9. Kishida Y, Natsume A, Kondo Y, Takeuchi I, An B, Okamoto Y, Shinjo K, Saito K, Ando H, Ohka F, Sekido Y, Wakabayashi T. Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. Carcinogenesis. 2012; 33: 436-41. PMID: 22102699.
        10. Okamoto Y, Sawaki A, Ito S, Nishida T, Takahashi T, Toyota M, Suzuki H, Shinomura Y, Takeuchi I, Shinjo K, An B, Ito H, Yamao K, Fujii M, Murakami H, Osada H, Kataoka H, Joh T, Sekido Y, Kondo Y. Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumour. Gut. 2012; 61: 392-401. PMID: 21708825.

        ▲ページ先頭へ

        2011年

        1. Konishi K, Watanabe Y, Shen L, Guo Y, Castoro RJ, Kondo K, Chung W, Ahmed S, Jelinek J, Boumber YA, Estecio MR, Maegawa S, Kondo Y, Itoh F, Imawari M, Hamilton SR, Issa JP. DNA methylation profiles of primary colorectal carcinoma and matched liver metastasis. PloS One. 2011; 6: e27889. PMID: 22132162.
        2. Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, Nakasu Y, Namba H, Wakai K, Fukui T, Momota H, Iwami K, Kinjo S, Ito M, Fujii M, Wakabayashi T. The Global DNA Methylation Surrogate LINE-1 Methylation Is Correlated with MGMT Promoter Methylation and Is a Better Prognostic Factor for Glioma. PloS One. 2011; 6: e23332. PMID: 21829728.
        3. Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, Feng H, Ching AK, Cheung KF, Wong HK, Tong JH, Jin H, Choy KW, Yu J, To KF, Wong N, Huang TH, Sung JJ. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cancer Res. 2011; 71: 4028-39. PMID: 21512140.
        4. Ju H, An B, Okamoto Y, Shinjo K, Kanemitsu Y, Komori K, Hirai T, Shimizu Y, Sano T, Sawaki A, Tajika M, Yamao K, Fujii M, Murakami H, Osada H, Ito H, Takeuchi I, Sekido Y, Kondo Y. Distinct profiles of epigenetic evolution between colorect cancers with and without metastasis. Am J Pathol. 2011; 178: 1835-46. PMID: 21406167.
        5. Nagashio R, Arai E, Ojima H, Kosuge T, Kondo Y, Kanai Y. Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage. Int J Cancer. 2011; 129: 1170-9. PMID: 21400512.
        6. Murakami M, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, Akatsuka S, Horio Y, Hida T, Kondo Y, Toyokuni S, Osada H, Sekido Y. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 2011; 71: 873-83. PMID: 21245096.
        7. Motomura K, Natsume A, Kishida Y, Higashi H, Kondo Y, Nakasu Y, Abe T, Namba H, Wakai K, Wakabayashi T. Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: a multicenter study. Cancer. 2011; 117: 1721-30. PMID: 21472719.

        ▲ページ先頭へ

        2010年

        1. Estecio MR, Gallegos J, Vallot C, Castoro RJ, Chung W, Maegawa S, Oki Y, Kondo Y, Jelinek J, Shen L, Hartung H, Aplan PD, Czerniak BA, Liang S, Issa JPJ. Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer. Genome Res. 2010; 20: 1369-82. PMID: 20716667.
        2. An B, Kondo Y, Okamoto Y, Shinjo K, Kanemitsu Y, Komori K, Hirai T, Sawaki A, Tajika M, Nakamura T, Yamao K, Yatabe Y, Fujii M, Murakami H, Osada H, Tani T, Matsuo K, Shen L, Issa JPJ, Sekido Y. Characteristic methylation profile in CpG island methylator phenotype-negative distal colorectal cancers. Int J Cancer. 2010; 127: 2095-105. vPMID: 20131317.
        3. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Hussain S, Estey E, Issa JPJ. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010; 28: 605-13. vPMID: 20038729.

        ▲ページ先頭へ

        2009年

        1. Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, Kondo Y, Osada H, Shimokata K, Horio Y, Hasegawa Y, Hida Y, Sekido Y. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Molecular Medicine Reports. 2009; 2: 181-8. PMID: 21475810.
        2. Ohno M, Natsume A, Kondo Y, Iwamizu H, Motomura K, Toda H , Ito M, Kato T, Wakabayashi T. The modulation of microRNAs by Type I Interferon through the activation of STAT3 in human glioma. Mol Cancer Res. 2009; 7: 2022-30. PMID: 19934272.
        3. Goto Y, Shinjo K, Kondo Y, Shen L, Toyota M, Suzuki H, Gao W, An B, Fujii M, Murakami H, Osada H, Taniguchi T, Usami N, Kondo M, Hasegawa Y, Shimokata K, Matsuo K, Hida T, Fujimoto N, Kishimoto T, Issa JPJ, Sekido Y. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res. 2009; 69: 9073-82. PMID: 19887624.
        4. Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, Kondo Y, Osada H, Usami N, Yokoi K, Ueda Y, Yatabe Y, Ito M, Horio Y, Hida T, Sekido Y. Combinational inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis. 2009; 30: 1097-105. PMID: 19380521.
        5. Yuki K, Natsume A, Yokoyama H, Kondo Y, Ohno M, Kato T, Chansakul P, Ito M, Kim S, Wakabayashi T. Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling. Cancer Lett. 2009; 284: 71-9. PMID: 19457609.
        6. Oi S, Natsume A, Ito M, Kondo Y, Shimato S, Maeda Y, Saito K, Wakabayashi T. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid with 5-aza-2’-deoxycytidine, in glioma cells. J Neurooncol. 2009; 92: 15-22. PMID: 19030781.

        ▲ページ先頭へ

        2008年

        1. Yokoyama T, Osada H, Murakami H, Tatematsu Y, Taniguchi T, Kondo Y, Yatabe Y, Hasegawa Y, Shimokata K, Horio Y, Hida T, Sekido Y. YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis. 2008 ; 29 : 2139-46 . PMID: 18725387.
        2. Yamamoto E, Toyota M, Suzuki H, Kondo Y, Sanomura T, Murayama Y, Ohe-Toyota M, Maruyama R, Nojima M, Ashida M, Fujii K, Sasaki Y, Hayashi N, Mori M, Imai K, Tokino T, Shinomura Y. LINE-1 hypomethylation is associated with increased CpG island methylation in helicobacter pylori-related enlarged-fold gastritis. Cancer Epidemiol Biomarkers Prev. 2008 ; 17 : 2555-64 . PMID: 18842996.
        3. Gao W, Kondo Y, Shen L, Shimizu Y, Sano T, Yamao K, Natsume A, Goto Y, Ito M, Murakami H, Osada H, Zhang J, Issa JPJ, Sekido Y. Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis. 2008 ; 29 : 1901-10 . PMID: 18632756.
        4. Boumber YA, Kondo Y, Chen X, Shen L, Guo Y, Tellez C, Estécio MR, Ahmed S, Issa JPJ. An Sp1/Sp3 binding polymorphism confers methylation protection. PLoS Genet. 2008 ; 4 : e1000162 . PMID: 18725933.
        5. Suehiro Y, Wong CW, Chirieac LR, Kondo Y, Shen L, Webb CR, Chan YW, Chan AS, Chan TL, Wu TT, Rashid A, Hamanaka Y, Hinoda Y, Shannon RL, Wang X, Morris J, Issa JPJ, Yuen ST, Leung SY, Hamilton SR. Epigenetic-Genetic Interactions in the APC/WNT, RAS/RAF, and P53 Pathways in Colorectal Carcinoma. Clin Cancer Res. 2008 ; 14 : 2560-9 . PMID: 18451217.
        6. Osada H, Tomida S, Yatabe Y, Tatematsu Y, Takeuchi T, Murakami H, Kondo Y, Sekido Y, Takahashi T. Roles of ASH1 in DKK1 and E-cadherin repression and neuroendocrine differentiation in lung cancer. Cancer Res. 2008 ; 68 : 1647-55 . PMID: 18339843.
        7. Natsume A, Wakabayashi T, Tsujimura K, Shimato S, Ito M, Kuzushima K, Kondo Y, Sekido Y, Kawatsura H, Narita Y, Yoshida J. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer. 2008 ; 122 : 2542-53 . PMID: 18240144.
        8. Kondo Y, Shen L, Cheng A, Ahmed S, Boumber Y, Charo C, Yamochi T, Urano T, Furukawa K, Kwabi-Addo B, Gold D, Sekido Y, Huang T, Issa JPJ. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008 ; 40 : 741-50 . PMID: 18488029.
        9. Kondo Y, Shen L, Ahmed S, Boumber Y, Sekido Y, Haddad BR, Issa JPJ. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS One. 2008 ; 3 : e2037 . PMID: 18446223.

        ▲ページ先頭へ

        2007年

        1. Kondo Y, Shen L, Suzuki S, Kurokawa T, Masuko K, Tanaka Y, Kato H, Mizuno Y, Yokoe M, Sugauchi F, Hirashima H, Orito E Osada H, Ueda R, Guo Y, Chen X, Issa JPJ, Sekido Y. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res. 2007 ; 37 : 974-83 . PMID: 17584191.
        2. Tabe Y, Konopleva M, Kondo Y, Contractor R, Tsao T, Konoplev S, Shi Y, Ling X, Watt JC, Tsutsumi-Ishii Y, Ohsaka A, Nagaoka I, Issa JPJ, Kogan SC, Andreeff M. PPARγ -active triterpenoid CDDO enhances ATRA-induced differentiation in APL. Cancer Biol Ther. 2007 ; 6 : 1967-77 . PMID: 18075297.
        3. Shen L, Kondo Y, Guo Y, Zhang J, Zhang L, Ahmed S, Shu J, Chen X, Waterland RA, Issa JPJ. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet. 2007 ; 3 : 2023-36 . PMID: 17967063.
        4. Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y, Chen X, Vilaythong JN, Issa JPJ. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res. 2007 ; 67 : 11335-43 . PMID: 18056460.
        5. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, Hernandez NS, Chen X, Ahmed S, Konishi K, Hamilton SR, Issa JPJ. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A. 2007 ; 104 : 18654-9 . PMID: 18003927.
        6. Watanabe Y, Toyota M, Kondo Y, Suzuki H, Imai T, Ohe-Toyota M, Maruyama R, Nojima M, Sasaki Y, Sekido Y, Hiratsuka H, Shinomura Y, Imai K, Itoh F, Tokino T. PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. Clin Cancer Res. 2007 ; 13 : 4786-94 . PMID: 17699856.
        7. Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K, Estey E, Kantarjian H, Garcia-Manero G, Issa JPJ. RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res. 2007 ; 67 : 1997-2005 . 17332327.
        8. Sato N, Fukui T, Taniguchi T, Yokoyama T, Kondo M, Nagasaka T, Goto Y, Gao W, Ueda Y, Yokoi K, Minna JD, Osada H, Kondo Y, Sekido Y. RhoB is frequently downregulated in nonsmall-cell lung cancer and resides in the 2p24 homozygous deletion region of a lung cancer cell line. Int. J. Cancer. 2007 ; 120 : 543-51 . PMID: 17096327.

        ▲ページ先頭へ

        2006年

        1. Tabe Y, Konopleva M, Kondo Y, Contractor R, Jin L, Ruvolo V, Tsutsumi-Ishii Y, Miyake K, Miyake N, Ohsaka A, Nagaoka I, Issa JPJ, Andreeff M. PML-RARα and AML1-ETO translocations are rarely associated with methylation of the RARβ2 promoter. Ann Hematol. 2006 ; 85 : 689-704 . PMID: 16832676.

        ▲ページ先頭へ

        2005年

        1. Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, Buckmeier J, Alberts DS, Hamilton SR, Issa JPJ. MGMT promoter methylation and the field defect in sporadic colorectal cancer. J Natl Cancer Inst. 2005 ; 97 : 1330-8 . PMID: 16174854.

        ▲ページ先頭へ

        2004年

        1. Kondo Y, Shen L, Yan PS, Huang TH, Issa JP. Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation. Proc Natl Acad Sci U S A. 2004 ; 101 : 7398-403 . PMID: 15123805.
        2. Yang AS, Estecio M, Doshi K, Kondo Y, Tajara EH, Issa JPJ. A simple method for assessing global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res. 2004 ; 32 : e38 . PMID: 14973332.
        3. Youssef EM, Chen XQ, Higuchi E, Kondo Y, Garcia-Manero G, Lotan R, Issa JPJ. Hypermethylation and silencing of the putative tumor suppressor (TIG-1) in human cancers. Cancer Res. 2004 ; 64 : 2411-7 . PMID: 15059893.

        ▲ページ先頭へ

        2003年

        1. Kondo Y, Issa JPJ. Enrichment for histone H3 lysine 9 methylation at Alu repeats in human cells. J Biol Chem. 2003 ; 278 : 27658-62 . PMID: 12724318.
        2. Kondo Y, Shen L, Issa JPJ. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol. 2003 ; 23 : 206-15 . PMID: 12482974.
        3. Suzuki S, Kondo Y, Hirashima N, Kato H, Sugauchi F, Orito E, Yang Y, Shen Y, Sakakibara K, Ueda R, Mizokami M. Evaluation of loss of heterozygosity before and after interferon therapy in patients with hepatitis C virus infection who developed hepatocellular carcinoma during follow up. J Gastroenterol Hepatol. 2003 ; 18 : 1364-72 . PMID: 14675264.
        4. Shen L, Kondo Y, Hamilton SR, Rashid A, Issa JPJ. P14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53. Gastroenterology. 2003 ; 124 : 626-33 . PMID: 12612901.
        5. Fujii S, Luo RZ, Yuan J, Kadota M, Oshimura M, Dent SR, Kondo Y, Issa JPJ, Bast RC Jr, Yu Y. Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Hum Mol Genet. 2003 ; 12 : 1791-800 . PMID: 12874100.
        6. Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, Imai K, Kantarjian HM, Issa JPJ, Garcia-Manero G. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood. 2003 ; 101 : 4131-6 . PMID: 12586619.

        ▲ページ先頭へ

        2002年

        1. Shen L, Kondo Y, Issa JPJ, Garcia-Manero G. Lack of p21 (CIP1) DNA methylation in acute lymphocytic leukemia. Blood. 2002 ; 100 : 3432-3 . PMID: 12412576.

        ▲ページ先頭へ

        2001年

        1. Kanai Y, Ushijima S, Kondo Y, Nakanishi Y, Hirohashi S. DNA methyltransferase expression and DNA methylation of CPG islands and peri-centromeric satellite regions in human colorectal and stomach cancers. Int J Cancer. 2001 ; 91 : 205-12 . PMID: 11146446.

        ▲ページ先頭へ

        2000年

        1. Zhu X, Kanai Y, Saito A, Kondo Y, Hirohashi S. Aberrant expression of β-catenin and mutation of exon 3 of the β-catenin gene in renal and urothelial carcinomas. Pathol Int. 2000 ; 50 : 945-52 . PMID: 11123760.
        2. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis-A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology. 2000 ; 32 : 970-9 . PMID: 11050047.

        ▲ページ先頭へ

        1999年

        1. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Microsatellite instability associated with hepatocarcinogenesis, J Hepatol. 1999 ; 31 : 529-36 . PMID: 10488714.
        2. Kondo Y, Kanai Y, Sakamoto M, Genda T, Mizokami M, Ueda R, Hirohashi S. β-catenin accumulation and mutation of exon 3 of the β-catenin gene in hepatocellular carcinoma. Jpn J Cancer Res. 1999 ; 90 : 1301-9 . PMID: 10665646.
        3. Nakano T, Park YM, Mizokami M, Choi JY, Orito E, Ohno T, Kato T, Kondo Y, Tanaka Y, Kato H, Kato T, Kim BS. TT virus infection among blood donors and patients with non-B, non-C liver diseases in Korea. J Hepatol. 1999 ; 30 : 389-93 . PMID: 10190719.
        4. Kato H, Mizokami M, Nakano T, Kondo Y, Dashnyam B, Oyunsuren T, Ueda R. High prevalence and phylogenetic analysis of TT-virus infection in Mongolia. Virus Res. 1999 ; 60 : 171-9 . PMID: 10392725.
        5. Kato T, Mizokami M, Orito E, Ohba K, Nakano T, Kondo Y, Tanaka Y, Ueda R, Mukaide M, Yasuda K, Iino S. Amino acid substitutions in NS5A region of GB virus C and response to interferon therapy. J Med Virol. 1999 ; 57 : 376-82 . PMID: 10089050.

        ▲ページ先頭へ

        1998年

        1. Suzuki K, Mizokami M, Sale MG, Kondo Y, Hattori K, Kun C, Tibbs CJ, Williams R. GB virus C/hepatitis G virus infection in patients with chronic hepatitis C virus infection. Hepatol Res. 1998 , 11 : 95-102 .
        2. Kondo Y, Mizokami M, Nakano T, Kato T, Ohba K, Orito E, Tanaka Y, Hirashima N, Ueda R, Kunimatsu M, Sasaki M, Yasuda K, Shiro S. Analysis of conserved ambisense sequences within GB virus C. J Infect Dis. 1998 ; 178 : 1185-8 . PMID: 9806057.
        3. Tanaka Y, Mizokami M, Orito E, Ohba K, Kato T, Kondo Y, Mboudjeka I, Zekeng L, Kaptue L, Bikandou B, M'Pele P,Takehisa J, Hayami M, Suzuki Y, Gojobori T. African origin of GB virus C/hepatitis G virus. FEBS Lett. 1998 ; 423 : 143-8 . PMID: 9512347.
        4. Tanaka Y, Mizokami M, Orito E, Ohba K, Nakano T, Kato T, Kondo Y, Ding X, Ueda R, Sonoda S, Tajima K, Miura T, Hayami M. GB virus C/hepatitis G virus infection among Colombian native Indians. Am J Trop Med Hyg. 1998 ; 59 : 462-7 . PMID: 9749645.
        5. Kato T, Mizokami M, Nakano T, Orito E, Ohba K, Kondo Y, Tanaka Y, Ueda R, Mukaide M, Fujita K, Yasuda K, Iino S. Heterogeneity in E2 region of GBV-C/hepatitis G virus and hepatitis C virus. J Med Virol. 1998 ; 55 : 109-17 . PMID: 9598930.

        ▲ページ先頭へ

        1997年

        1. Nakano T, Mizokami M, Orito E, Ohba K, Kondo Y, Kato T, Tanaka Y, Wakita A, Komatsu H, Nitta M, Ueda R. GB virus C/hepatitis G virus infection among Japanese patients with hematological diseases. Hepatol Res. 1997 ; 9 : 180-91 .
          2. .
        2. Kondo Y, Mizokami M, Nakano T, Kato T, Ueda R, Mukaide M, Hikiji K, Ishida I, Dorjsuren D, Dashnyam B, Oyunsuren T. Prevalence and molecular epidemiology of GB virus C/hepatitis G virus infection in Mongolia. J Med Virol. 1997 ; 52 : 143-8 . PMID: 9179759.
        3. Kondo Y, Mizokami M, Nakano T, Kato T, Ohba K, Orito E, Ueda R, Mukaide M, Hikiji K, Oyunsuren T, Cooksley W.G. Genotype of GB virus C/hepatitis G virus by molecular evolutionary analysis. Virus Res. 1997 ; 52 : 221-30 . PMID: 9495537.
        4. Orito E, Mizokami M, Yasuda K, Sugihara K, Nakamura M, Mukaide M, Ohba K, Nakano T, Kato T, Kondo Y, Kumada T, Ueda R, Iino S. Interferon-α therapy in patients dually infected with hepatitis C virus and GB virusC/hepatitis G virus- virological response of HGV and pretreatment HGV viremia level. J Hepatol. 1997 ; 27 : 603-12 . PMID: 9365035.
        5. Kato T, Mizokami M, Nakano T, Kondo Y, Ohba K, Orito E, Ueda R, Mukaide M, Gurtsevitch V, Syrtsev A, Ruzibakiev R, Abdurakhnamov M, Yamashita M, Hayami M. High prevalence of GB virus C/hepatitis G virus infection among the Jewish population in Uzbekistan. Virus Res. 1997 ; 48 : 81-7 . PMID: 9140196.


        ▲ページ先頭へ

        著書

        【欧文著書】

        1. Ohka F, Natume A,Kondo Y. Chapter 15: Clinical Significance of Epigenetic Alterations in Glioblastoma. Gray. Epigenetic Cancer Therapy. Academic Press. 339-350. 2015.
        2. Okamoto Y, Kondo Y. General Mechanisms of Cancers - Genetic and epigenetic alterations in inflammation-related cancers –. Cho CH, Yu J, From Inflammation to Cancer: Advances in Diagnosis ＆ Therapy for Gastrointestinal and Hepatological Diseases. World Scientific Publishing. 29-48. 2012.
        3. Kondo Y. Chapter 12 - Epigenetic Changes in Hepatic Tissues: Evidence of Field Cancerization. Dakubo GD. Field Cancerization: Basic Science and Clinical Applications. Nova Science Publishers. 178-192. 2010.
        4. Kondo Y. Chromatin Remodeling. Schwab M. Encyclopedia in Cancer. Springer. 662-665. 2009.
        5. Suzuki H, Toyota M, Kondo Y, Shinomura Y. Chapter 5: Inflammation-related aberrant patterns of DNA methylation: detection and role in epigenetic deregulation of cancer cell transcriptome. Kozlov SV. Methods in Molecular Medicine. Humana Press. 55-69. 2009.
        6. Kondo Y, Issa JPJ. Chapter 5: Chromatin immunoprecipitation for microarray analysis. Winegarden NA, Takahashi M. Promoter and CpG Island Microarrays. DNA Press. 77-88. 2006.

        ▲ページ先頭へ

        【和文著書】

        1. 鈴木美穂、近藤　豊.エピゲノムで新たな解明が進む「先天性疾患」（副島英伸、秦　健一郎　編）.　ヒス トンメチル化制御阻害剤. 株式会社メディカルドゥ. 遺伝子医学MOOK 36. 204-209. 2021.
        2. 新城恵子、近藤　豊.「エピゲノム標的薬」（清宮啓之　編）進化するがん創薬－がん科学と薬物療法の最前線.　株式会社化学同人. 224-233. 2019.
        3. 田崎慶彦、勝島啓祐、木村和哲、近藤　豊. がん幹細胞とエピゲノム制御. 日本臨牀　がん転移学. 2017 ; Vol 75, No. 8 : 137-143.
        4. 間瀬聖子、近藤　豊. DNAメチル化によるがん診断. 次世代がん治療. 2017 ; 327-334
        5. 新城恵子、近藤　豊.「血中ＤＮＡメチル化解析とがん診断」（落谷孝広　監修）リキッドバイオプシー　－体液中腫瘍マーカーの検出・解析技術－. 株式会社シーエムシー出版. 206-212. 2017.
        6. 大岡史治、近藤　豊.「がん幹細胞を制御するエピゲノム機構―グリオーマのエピゲノム治療に向け て」（柴田龍弘 編）がんゲノム研究の進歩―網羅的解析からの知見. 医歯薬出版株式会社.57-62. 2015.
        7. 勝島啓佑、近藤　豊.「がんのヒストン異常」（畑田出穂、久保田健夫　編）エピジェネティクスの産業応用.シーエムシー出版.173-181. 2014.
        8. 近藤　豊. 「ヒストンメチル化酵素EZH2の発がんにおける役割と治療標的としての可能性」（柴田龍弘 編）個別化医療を拓くがんゲノム研究. 実験医学(増刊). 羊土社.144-150. 2014
        9. 大岡史治、近藤　豊. 「脳腫瘍の発生に関わるエピジェネティクス異常」（佐々木裕之、中尾光善、中島欽一　編）エピジェネティクスと病気. メディカルドゥ社. 76-81. 2014.
        10. 近藤　豊.「がんにおけるエピジェネティクス異常と医療応用」（牛島俊和、眞貝洋一 編）イラストで徹底理解する エピジェネティクスキーワード事典. 羊土社.170-179. 2013.
        11. 近藤　豊.「がん細胞のエピゲノム異常」「がんエピゲノム可塑性を標的とした治療法の開発」（清木元治、秋山 徹、石川冬木、内海潤、近藤 豊、中山敬一、平尾 敦　編）がん基盤生物学―革新的シーズ育成に向けて. 南山堂. 209-219. 2013.
        12. 近藤　豊、新城恵子.「がん」（牛島俊和、眞貝洋一　編）イラストで徹底理解する エピジェネティクスキーワード事典　～分子機構から疾患・解析技術まで.羊土社.170-179.2013.
        13. 近藤　豊. 「造血器腫瘍とエピジェネティクス」（木崎昌弘 編）エピジェネティック異常のがん診断への応用. 株式会社医薬ジャーナル社. 27-39. 2012.
        14. 新城恵子、近藤　豊．「エピジェネティクスのがん診断への応用」（牛島俊和、塩田邦郎 編）エピジェネティクスと疾患. 羊土社. 144-53. 2010.
        15. 近藤　豊. 「Pyrosequencing （パイロシークエンス法）」 (牛島俊和、眞貝洋一 編) エピジェネティクス実験プロトコール. 羊土社. 77-91. 2008.
        16. 近藤　豊. 「ヒストンのメチル化とアセチル化」 （押村光雄 編） わかる実験医学シリーズ：注目のエピジェネティクスがわかる. 羊土社. 37-44. 2004.
        17. 近藤　豊、溝上雅史. 「肝炎」 （茂田士郎、森島恒雄　編） ウイルス感染症. 医薬ジャーナル社. 240-255. 1997.



        ▲ページ先頭へ

        総説

        【欧文総説】

        1. Peng Y, Tang D, Zhang M, Kajiyama H, Kikkawa F, Kondo Y. Long Non-Coding RNA: A Recently Accentuated Molecule in Chemoresistance in Cancer. Cancer Metastasis Rev. 2020;**:****-****, PMID: 32594276.
        2. Kondo Y. Genome-Epigenome-Senescence: Is TET1 a Caretaker of p53-Injured Lung Cancer Cells? Cancer Res. 2019;79:1751-1752, PMID: 30987976.
        3. Herceg Z, Ghantous A, Wild CP, Sklias A, Casati L, Duthie SJ, Fry R, Issa JP, Kellermayer R, Koturbash I, Kondo Y, Lepeule J, Lima SCS, Marsit CJ, Rakyan V, Saffery R, Taylor JA, Teschendorff AE, Ushijima T, Vineis P, Walker CL, Waterland RA, Wiemels J, Ambatipudi S, Degli Esposti D, Hernandez-Vargas H. Roadmap for investigating epigenome deregulation and environmental origins of cancer. Int J Cancer. 2018 Mar 1 ; 142 : 874-82, PMID: 28836271.
        4. Kondo Y, Shinjo K, Katsushima K. Long non-coding RNAs as an epigenetic regulator in human cancers. Cancer Sci. 2017; 108: 1927-1933, PMID: 28776911.
        5. Shinjo K, Kondo Y. Targeting cancer epigenetics: Linking basic biology to clinical medicine. Adv Drug Deliv Rev. 2015 ; 95 : 56-64. PMID: 26494398.
        6. Katsushima K, Kondo Y. Non-coding RNAs as epigenetic regulator of glioma stem-like cell differentiation. Front Genet. 2014 ; 5 : 14 . eCollection. PMID: 24550934.
        7. Kondo Y. Shall we crosstalk? - The relationship between DNA methylation and histone H3 lysine 27 trimethylation. Bioessays. 2014 ; 36 : 128 . PMID: 24343874.
        8. Kondo Y, Katsushima K, Ohka F, Natsume A, Shinjo K. Epigenetic dysregulation in glioma. Cancer Sci. 2014;105: 363-9. PMID: 24843883.
        9. Kondo Y. Targeting histone methyltransferase EZH2 as cancer treatment. J Biochem. 2014;156: 249-57. PMID: 25179367.
        10. Shinjo K, Kondo Y. Clinical implications of epigenetic alterations in human thoracic malignancies: epigenetic alterations in lung cancer. Methods Mol Biol. 2012; 863: 221-39. PMID: 22359296.
        11. Fujii M, Nakanishi H, Toyoda T, Tanaka I, Kondo Y, Osada H, Sekido Y. Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFβ signaling and defects in the Hippo signaling cascade. Cell Cycle. 2012; 11: 3373-9. PMID: 22918238.
        12. Kondo Y, Issa JPJ. DNA methylation profiling in cancer. Expert Rev Mol Med. 2010; 12: e23. PMID: 20663272.
        13. Natsume A, Kondo Y, Ito M, Motomura K, Wakabayashi T, Yoshida J. Epigenetic aberrations and therapeutic implications in gliomas. Cancer Sci. 2010; 101: 1331-6. PMID: 20384628.
        14. Kondo Y. Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med J. 2009; 50: 455-63. PMID: 19718392.
        15. Kondo Y, Issa JP. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 2004; 23: 29-39. PMID: 15000147.

        ▲ページ先頭へ

        【和文総説】

        1. 新城　恵子、近藤　豊.「膵癌における血中KRAS変異を含めた新たな遺伝子診断法の開発 ．胆と膵. 2023 ;　Vol 44（7） : 647-652-22.．
        2. 新城　恵子、近藤　豊. 遺伝を考える”エピジェネティクス”．日本医師会雑誌. 2023 ;　第152巻・特別号（1）生涯教育シリーズ104,S50-S55．
        3. 新城　恵子. 論文図表を読む作法、”デジタルPCR”．羊土社. 2022 ;　38-39.
        4. 新城　恵子、近藤　豊. 疾患原因遺伝子・タンパク質の解析技術と創薬/診断技術への応用　”がんの発症に関与するエピゲノム異常の探索-非翻訳RNAによるエピゲノム制御-”．技術情報協会. 2022 ;　60-68.
        5. 新城　恵子、近藤　豊. リアルタイム・デジタルPCR実験スタンダード”デジタルPCRを用いたCfDNAのDNAメチル化解析”．羊土社. 2022 ;　265-273.
        6. 鈴木　美穂、近藤　豊．ヒストンメチル化制御阻害剤.遺伝子医学MOOK36号「エピゲノムで新たな解明が進む『先天性疾患』」. 2021 .
        7. 飯島健太、近藤　豊. Non-coding RNAの多様な機能とゲノム安定性維持における役割. 医学のあゆみ. 2020 ; Vol 272, No. 1 : 17-22.
        8. 勝島啓佑、鈴木美穂、近藤　豊. EZH2阻害剤の作動原理と開発現状. 医学のあゆみ. 2018 ; Vol 266, No. 11 : 18932-18938.
        9. 鈴木美穂、勝島啓佑、近藤　豊. 長鎖非コード RNA をターゲットにした膠芽腫の治療. Medical Science Digest. 2018 ; 44 : 238-240.
        10. 勝島啓佑、近藤　豊. 長鎖非翻訳RNAを標的とする革新的核酸治療薬の開発. BIO Clinica. 2018 ; 1月号, 28-33.
        11. 近藤　豊. 核酸化合物の医療への応用. BIO Clinica. 2018 ; 1月号, 4-5.
        12. 新城恵子、近藤　豊. パイロシークエンス法 複数のCpGメチル化の定量. エピジェネティクス実験スタンダード. 2017 ; 64-73.
        13. 勝島啓佑、近藤　豊. 長鎖非翻訳RNAを標的としたがん治療薬の開発. 腫瘍内科. 2017 ; Vol 19, No. 4 : 454-461.
        14. 戸谷治仁、近藤　豊. がんのエピゲノム解読と新薬開発. 血液内科. 2016 ; Vol 72, No. 4 : 524-532.
        15. 新城恵子・近藤　豊. 脳腫瘍におけるエピゲノム異常と治療への展望. 羊土社.　2016 ; 32 : 1599-1604.
        16. 出口彰一・近藤　豊. 膠芽腫における長鎖非翻訳RNAとエピゲノム制御異常. 日本薬理学会誌.　2016 ; Vol 147, No. 6 : 357-361.
        17. 勝島啓佑、近藤　豊. エピゲノム異常によるがん診断. 医学のあゆみ. 2015 ; Vol 255, No. 6 : 595-601.
        18. 新城恵子・近藤　豊. エピゲノム制御と癌の最前線. Frontiers in Gastroenterology, 2015 ; Vol 20, No. 1 : 45-52.
        19. 勝島啓佑、近藤　豊. がんのヒストン修飾異常. エピジェネティクスの産業応用. 2014 ; 173-181.
        20. 出口 彰一、近藤 豊、夏目 敦至. 神経膠腫におけるエピジェネティクス機構とnon-coding RNAs. 脳神経外科. 2014 ; 42(8) : 701-709.
        21. 市村典久、近藤　豊. エピゲノム異常を標的としたがん治療. 脳神経外科. 実験医学. 2014 ; 32 : 3054-3060.
        22. 大岡史治、近藤　豊. がん幹細胞を制御するエピゲノム機構‐グリオーマのエピゲノム治療に向けて. 医学のあゆみ. 2014; 249: 1067-1072.
        23. 近藤　豊. エピジェネティクスから迫るがん診断. 現代化学. 2013 ; 504 : 46-50.
        24. 近藤　豊. 骨髄異形成症候群の遺伝子異常と分子病態. メディカル・サイエンス・ダイジェスト. 2012; 38 : 9-12.
        25. 岡本泰幸、安 炳九、近藤　豊. 遺伝子背景からみた大腸癌の左右差. 胃と腸. 2012 ; 47 : 1983-88.
        26. 近藤　豊. がん細胞におけるエピゲノム異常. 実験医学. 2012 ; 30 : 44-51.
        27. 近藤　豊. DNAメチル化異常のがん診断への応用. 血液フロンティア. 2011 ; 21 : 33-43.
        28. 近藤　豊. がん細胞のエピゲノム異常を標的とした新しいがん治療戦略. 医工学治療. 2011 ; 36 : 208-16.
        29. 近藤　豊. エピジェネティックセラピーの現状と展望. メディカル・サイエンス・ダイジェスト. 2010 ; 36 : 12-15.
        30. 新城恵子、近藤　豊. がん細胞の可塑性とエピジェネティクスを標的とする治療開発. 癌と化学療法. 2010 ; 37 : 1654-8.
        31. 岡本泰幸、近藤　豊. 消化器癌にみられるヒストン修飾の解明. G.I.Research. 2009 ; 17 : 47-53.
        32. 岡本泰幸、近藤　豊. エピジェネティクス異常を標的とした新規治療法への期待. Surgery Frontier. 2009 ; 16 : 70-3.
        33. 安　炳九、近藤　豊.DNAメチル化を利用した癌診断. 分子消化器病. 2008 ; 5 : 376-83.
        34. 近藤　豊. がんにおけるエピジェネティクス異常. 医学のあゆみ. 2008 ; 225 : 551-8.
        35. 近藤　豊. がんにおけるヒストン修飾異常の役割. 最新医学. 2008 ; 63 : 763-70.
        36. 近藤　豊. ヒストン修飾と消化器癌. 細胞. 2007 ; 39 : 9-14.
        37. 近藤　豊. エピジェネティクスを利用したがんの診断と治療. Surgery Frontier. 2006 ; 13 : 80-5.
        38. 近藤　豊. 造血器腫瘍におけるエピジェネティクスの役割. がん分子標的治療. 2005 ; 3 : 202-10.


▲ページ先頭へ

Copyright © SINCE 2017 NAGOYA UNIVERSITY. YUTAKA KONDO LAB All Rights Reserved.